Mammary Cell News 10.32 August 16, 2018 | |
| |
TOP STORYCirculating adipose fatty acid binding protein released by adipose tissue directly targeted mammary tumor cells, enhancing tumor stemness and aggressiveness through activation of the IL-6/STAT3/ALDH1 pathway. [Cell Metab] Abstract | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Researchers demonstrated that constitutive IRE1 RNase activity contributes to basal production of pro-tumorigenic factors IL-6, IL-8, CXCL1, GM-CSF, and TGFβ2 in triple-negative breast cancer cells. They showed that the chemotherapeutic drug, paclitaxel, enhanced IRE1 RNase activity and this contributed to paclitaxel-mediated expansion of tumor-initiating cells. [Nat Commun] Full Article | Press Release K-HRPRD1B depletion promoted BRCAness, where extensive upregulation of poly(ADP-ribose) polymerase 1 (PARP1) activity was required for survival of breast cancer cells. PARP inhibition in these cells led to synthetic lethality that was rescued by wild-type K-H re-expression, but not by a mutant K-H that weakly bound RNAPII. [Clin Cancer Res] Abstract Prolactin stimulated parathyroid hormone-related protein (PTHrP) transcript and protein in breast cancer cell lines in vitro and in vivo, effects were mediated by Stat5 through the P2 gene promoter, producing transcript AT6 encoding the PTHrP 1-173 isoform. Low levels of AT6, but not two alternative transcripts, correlated with poor clinical outcome. [Clin Cancer Res] Abstract CEP55 Is a Determinant of Cell Fate during Perturbed Mitosis in Breast Cancer CEP55 sensitized breast cancer cells to anti-mitotic agents through premature CDK1/cyclin B activation and CDK1 caspase-dependent mitotic cell death. Blocking MEK1/2-PLK1 signaling reduced outgrowth of basal-like syngeneic and human breast tumors in in vivo models. [EMBO Mol Med] Full Article | Graphical Abstract Investigators showed that breast cancer cell lines highly resistant to NK cells were significantly enriched in actin response-competent cells as compared to susceptible cell lines. The actin response was not associated with a defect in NK cell activation but correlated with reduced intracellular levels of the cytotoxic protease Granzyme B and a lower rate of apoptosis in target cells. [Cancer Res] Abstract Elevated level of phosphatidylinositol-4-phosphate 5-kinase 1 alpha (PIP5K1α) increased expression of pSer-473 AKT and invasiveness of triple-negative MDA-MB-231 cells. In ER+ cancer cells, PIP5K1α acted on pSer-473 AKT, and was in complexes with VEGFR2, serving as co-factor of ER-alpha to regulate activities of target genes including cyclin D1 and CDK1. [Oncogene] Full Article MCF-7 and MDA-MB-231 cells incubated in serum-containing media supplemented with fatty acids (FAs) accumulated extracellular FAs as intracellular triacylglycerols (TAGs) in a dose-dependent manner, with MDA-MB-231 cells accumulating more TAGs. [Mol Oncol] Abstract | Full Article Researchers found that induction of miR-9 and miR-221 mimics conferred side-population cells to form spheroidal tumor colonies in suspension culture that maintained the mesenchymal stem-cell potential in non-invasive MCF-7 breast cancer cells. [Cell Physiol Biochem] Full Article Scientists revealed that miR-342-3p directly targets the monocarboxylate transporter 1 (MCT1), which promoted lactate and glucose fluxes alteration, thus disrupting the metabolic homeostasis of tumor cells. They found that hypoxic conditions and glucose starvation attenuated miR-342-3p expression, suggesting a crosstalk program between these metabolic factors. [Sci Rep] Full Article Negatively charged gold nanoparticles (AuNPs) increased the expression of MKP-1, dephosphorylated and deacetylated histone H3 at Ser10 and K9/K14 residues respectively whereas, positively charged AuNPs decreased the expression of MKP-1, phosphorylated and acetylated histone H3 at Ser 10 and K9/K14 residues respectively. [Sci Rep] Full Article Notch3 knockdown downregulated GATA binding protein 3 (GATA-3) and promoted epithelial-mesenchymal transition (EMT); while overexpression of Notch3 intracellular domain upregulated GATA-3 and inhibited EMT, leading to a suppression of metastasis in vivo. [Oncogenesis] Full Article Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News. | |
| |
REVIEWSRole of Hypoxia-Induced Exosomes in Tumor Biology Hypoxia is a major regulator of angiogenesis and always influences the release of exosomes in various types of tumors. The authors assess the role of hypoxia-induced exosomes in the tumor biology. [Mol Cancer] Full Article Is There a Role for Immunotherapy in HER2-Positive Breast Cancer? Although the prognosis and prediction of therapeutic benefit for breast cancer patients overexpressing the human epidermal growth factor receptor 2 (HER2) have dramatically changed with the administration of anti-HER2-targeted therapies, HER2-positive metastatic breast cancer is still an incurable disease. [npj Breast Cancer] Full Article Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
INDUSTRY NEWSJHL Biotech has announced it received a positive Scientific Advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency related to the EU approval pathway for its proposed trastuzumab biosimilar, JHL1188, to treat breast cancer. [JHL Biotech, Inc. (PR Newswire Association LLC)] Press Release Celltrion Begins Global Phase III Clinical Trial for Its Bevacizumab Biosimilar ‘CT-P16’ Celltrion, Inc. is set to launch global Phase III clinical trial for its bevacizumab biosimilar ‘CT-P16’ for the treatment of cancer. Celltrion successfully completed Phase I clinical study on the safety and pharmacokinetic assessment of CT-P16 in June 2018. [Celltrion Inc.] Press Release Health researchers and laboratories are at the forefront of scientific breakthroughs that lead to new treatments and knowledge that form the cornerstone of health improvements for Canadians. The Honourable Ginette Petitpas Taylor, Minister of Health, announced an investment of $378 million, to support 405 health research projects across the country. [Government of Canada] Press Release | |
| |
POLICY NEWSWhat Pakistan’s New Government Means for Science Pakistan is reeling from a political earthquake — and researchers are both nervous and excited. On 18 August, the former cricket superstar Imran Khan is expected to be sworn in as prime minister. The incoming administration promises to use science to alleviate poverty, but it is facing an imminent economic crisis. [Nature News] Editorial The NIH Loosens Grip on Gene Therapy Trials The directors of the National Institutes of Health (NIH) and the US FDA propose limiting the role of the NIH in assessing proposals for gene therapy experiments, the two explain in a commentary in the New England Journal of Medicine. [The Scientist] Editorial Hundreds of Researchers from Harvard, Yale and Stanford Were Published in Fake Academic Journals In the so-called “post-truth era,” science seems like one of the last bastions of objective knowledge, but what if science itself were to succumb to fake news? Over the past year, German journalist Svea Eckert and a small team of journalists went undercover to investigate a massive underground network of fake science journals and conferences. [Vice Media LLC] Editorial How Unpaywall Is Transforming Open Science Unpaywall has become indispensable to many academics, and tie-ins with established scientific search engines could broaden its reach. On 26 July, Elsevier announced plans to integrate Unpaywall into its Scopus database searches, allowing it to deliver millions more free-to-read papers to users than it does currently. [Nature News] Editorial Iranian Students Protest US Visa Slowdown The rate at which the US government grants visas to prospective students from Iran has declined dramatically during President Donald Trump’s time in office, according to US government data. And the visas that are granted take more time to arrive, according to a group of Iranian students that is petitioning the Trump administration to speed up the process. [Nature News] Editorial
| |
EVENTSNEW The Tumor Cell: Plasticity, Progression and Therapy Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESPostdoctoral Fellow/Research Scientist – Cancer Research (Icahn School of Medicine at Mount Sinai) Postdoctoral Positions – Breast Cancer Research (UPMC Hillman Cancer Center) Cancer Faculty Investigators – Cancer Research (University of Alabama at Birmingham) Postdoctoral Research Fellow – Immuno/Oncology of Breast Cancer (Henry M. Jackson Foundation) Research Assistant/Associate – Breast Cancer Therapeutics (King’s College London) Postdoctoral Position – Breast Cancer (University of Trento) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|